Table 1 Baseline characteristics of the study participants.
pSS patients | Healthy controls | |
|---|---|---|
Number of cases | 8 | 16 |
Age (year, IQR) | 58 (48–65) | 59 (45–68) |
Women (n, %) | 8 (100) | 16 (100) |
Smoking (n, %) | 0 (0) | 0 (0) |
Autoimmune diseases other than pSS (n, %) | 0 (0) | 0 (0) |
Received immunomodulators/immunosuppressants or corticosteroids in last 3 months (n, %) | 0 (0) | 0 (0) |
Received antibiotics in last 3 months (n, %) | 0 (0) | 0 (0) |
Duration of clinically apparent xerostomia (months, IQR) | 12 (11–36) | 0 (0–0) |
Sialoscintigraphy gradesa | ||
<grade II (n, %) | 3 (43) | NA |
=grade II (n, %) | 3 (43) | NA |
>grade II (n, %) | 1 (14) | NA |
ESSDAI (point, IQR) | 0 (0–4) | NA |
Serology tests | ||
ANA titer ≥ 1:160 (n, %) | 2 (25) | NA |
Positivity of anti-Ro (n, %) | 4 (50) | NA |
Positivity of anti-La (n, %) | 2 (25) | NA |
Positivity of RF (n, %) | 2 (25) | NA |
LSG biopsy focus score ≥1 (n, %) | 4 (50) | NA |
